Peptide Brain-Barrier Transport: What the Measurements Show

Define the barrier claim precisely

A fluorescent signal in endothelial cells is not the same as intact peptide in brain parenchyma, and neither proves target engagement. Useful evidence distinguishes receptor binding, transcytosis or barrier modulation, tissue distribution, intact-molecule quantitation, and functional response.

Measured findings

Tanaka et al. (2019) tested 18 dipeptides in 2-minute in-situ mouse brain perfusions at 200 µM. Gly-Sar, Gly-Pro, and Tyr-Pro had influx clearances of 7.60 ± 1.29, 3.49 ± 0.66, and 3.53 ± 0.74 µL/g·min, respectively (n=4), and Tyr-Pro was detected in multiple mouse brain regions by MALDI-MS/MS imaging. The model measured transport under controlled perfusion; it did not establish systemic dosing, safety, or human delivery.

In a separate mouse study, intravenous E-cadherin HAV peptide increased marker accumulation by approximately 2- to 5-fold, with disruption appearing within 3–6 minutes and barrier integrity restored within 60 minutes. Those time and fold-change values are useful for designing a measurement plan, but they describe reversible barrier modulation in mice, not a therapeutic window.

Staffing implications

The evidence chain needs peptide chemistry, barrier-model biology, quantitative bioanalysis, neuroscience, and safety review. A coordinator can reconcile nominal dose, actual perfusion or injection time, tissue collection, species, region, and assay batch. Scientific owners must decide whether an apparent signal is transport, leakage, binding, or productive delivery.

Evidence limits

Both highlighted results are preclinical and model-specific. BBB models differ in species, flow, barrier integrity, and endpoint definition. FDA and ICH guidance supply development context; they do not validate a particular carrier peptide.

Source register

The ten sources above are reserved for this article and combine primary transport studies, open full text, safety guidance, and FDA clinical-pharmacology context.

Read the endpoint with its comparator

The Gly-Sar result is an influx clearance of 7.60 ± 1.29 µL/g·min at 200 µM in four perfused mice; the same experiment reported 3.49 ± 0.66 for Gly-Pro and 3.53 ± 0.74 for Tyr-Pro. Those values are measured against an in-situ perfusion design, not a clinical comparator. Preserve peptide identity, concentration, duration, n, units, tissue endpoint, and assay confirmation. A fluorescence increase alone should not be relabeled as intact parenchymal delivery.

The reported 2–5-fold marker increase after intravenous HAV peptide occurred within a reversible mouse barrier-modulation experiment, with disruption at 3–6 minutes and recovery by about 60 minutes. A transient permeability change and a sustained transport route have different safety implications. Support staff can reconcile dose, collection time, brain region, plasma sample, and image or mass-spectrometry file; neuroscience and bioanalysis owners interpret leakage, transport, and target engagement.